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ABSTRACT The WHO has declared tuberculosis (TB) a global health emergency. Therefore, there is an urgent need to 
discover and develop new anti-TB drugs. Here we report on a new category of 5-substituted pyrimidine nucleosides 
as potent inhibitors of Mycobacterium tuberculosis growth in vitro. A series of 2´-deoxy-, 3´-azido-2´,3´-dideoxy-, and 
3´-amino-2´,3´-dideoxypyrimidine nucleoside analogues bearing lengthy flexible alkyloxymethyl substituents exhib-
ited marked inhibitory activity against M tuberculosis in vitro. 5-Dodecyloxymethyl-2´-deoxyuridine was found to be 
a potent inhibitor of M. tuberculosis propagation in vitro. In contrast, monophosphates of the tested nucleosides were 
devoid of antimycobacterial activity. This new class of inhibitors seems to be a promising chemotherapeutic agent 
against TB and merits further studies.
KEYWORDS tuberculosis; Mycobacterium tuberculosis; anti-TB drug; nucleoside; 5-substituted pyrimidine; inhibitor
ABBREVIATIONS TB - tuberculosis, HIV - human immunodeficiency virus, MDR - multi-drug resistance, MIC - minimal 
inhibitory concentration, CFU - colony-forming unit 
INTRODUCTION
Tuberculosis (TB) is one of the largest problems facing mod-
ern health services. At the beginning of the 21st century, 
TB is one of the most widespread infectious diseases: about 
one-third of the world’s population (more than two billion 
people) is currently infected with Mycobacterium tubercu-
losis. According to WHO reports, about nine million people 
are infected every year, and more than two million people, of 
whom 10% are also infected with HIV, die from tuberculosis 
[1, 2]. Infection with HIV increases the chance of latent TB re-
activation [3] or leads to rapid TB development soon after (re)
infection with the TB bacillus [4]. Latent-to-active TB transi-
tion risk reaches 50% among people with AIDS and is about 
10% among the rest of the population.
Effective and accessible TB treatment schemes based on 
combinations of different drugs were developed at the begin-
ning of the 1950s. More than ten anti-TB drugs may be includ-
ed in the chemotherapy scheme [5]. Since this time, the broad 
use of anti-TB drugs, as well as vaccination, has led to a signifi-
cant decrease in TB-related mortality. On the other hand, the 
drug usage induced the selection of strains resistant to several 
pharmaceuticals of various types. HIV infected, drug-depend-
ent, and transplant patients have extremely weakened immu-
nities and, hence, become TB victims. These circumstances led 
to the fact that the frequency of TB cases started to grow at 
the end of the 1980s. The WHO announced a global TB health 
emergency in 1993. New Mycobacterium tuberculosis strains 
should be particularly noted: multidrug and extensively drug-
resistant tuberculosis (M/XDR-TB) strains [1] that are barely 
affected by standard chemotherapy schemes. M/XDR-TB 
generally results from incorrect treatment, when patients 
receive insufficient amounts of anti-TB drugs [6]. Usually, it 
takes more than half a year from the beginning of anti-TB 
treatment until the patient recovers, and during this time any 
contact with an infected patient can result in contamination [5]. 
The main factor determining resistance development under 
the action of anti-TB pharmaceuticals is the selection of drug-
resistant mycobacteria with genome mutations.
TB is one of the largest problems in Russia, because its cur-
rent incidence rate is 190.5, prevalence is 85.1, and mortality 
rate is 17.9 cases per 100 000 people. At the same time, the 
occurrence of MDR-TB is 13.6% in the patients with new TB 
cases and 28.8% in patients with relapses, according to the 
statistics of the Ministry of Health and Social Development of 
the Russian Federation [7]. In connection with the above, the 
search for new anti-TB drugs is necessary.
Therapy for viral infections is frequently based on us-
ing natural nucleoside derivatives [8]. The anti-TB activity 
of nucleosides has not been revealed until recently. Recent 
reports have appeared on several groups of modified nucle-
osides displaying a remarkable anti-mycobacterial effect in 
experimental models [9–14].
Recently, 5-modified pyrimidine nucleosides with lengthy 
1-alkinyl radicals have demonstrated an inhibitory effect on 
Mycobacterium tuberculosis and M. bovis in vitro [11–14]. The 
best antibacterial activity has been demonstrated for nucle-RESEARCH ARTICLES
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oside 5-(1-dodecynyl) and 5-(1-tetradecynyl) derivatives. 
The study on the influence of the carbohydrate fragment 
modification on the antibacterial properties of 5-modificed 
nucleosides has demonstrated that virtually all 2´-deoxy-, 
2´,3´-dideoxy-, 3´-fluoro-2´,3´-dideoxy-, and 2´-fluoro-
2´,3´-dideoxynucleosides, as well as acyclic and arabinonucl-
eosides with long 1-alkynyl radicals, have displayed anti-TB 
activity [11–14]. This work is devoted to an investigation of 
the Mycobacterium tuberculosis growth inhibitory capability 
of newly synthesized 2´-deoxy-, 3´-azido-2´,3´-dideoxy-, and 
3´-amino-2´,3´-dideoxy-pyrimidine nucleosides containing 
lengthy alkyloxymethyl radicals at their position 5.
MATERIALS AND METHODS
Tested substances (Fig. 1, 1–10). 5-(1-Dodecynyl)- and 
5-(1-tetradecynyl)-2´-deoxyuridine (1 and 2, respective-
ly) used as a control were prepared by the method in [11]. 
5-Alkyloxymethyl-pyrimidine nucleoside derivatives (6–10) 
were synthesized using our method in [15], and nucleoside 
5´-monophosphates (3–5) were synthesized by the method 
in [15–16].
Mycobacterial strain. These substances were tested using 
the Mycobacterium tuberculosis H37Rv laboratory strain sen-
sitive to anti-TB drugs. A suspension of individual mycobac-
terial cells was equalized by the growth phase and standard-
ized by CFU [17]. Cells were grown in a liquid medium Dubos 
with 5% BSA (Difco).
Estimation of antibacterial effect of tested substances. The 
effect that these substances have on the growth of the myco-
bacterial strain was examined using a BACTEC™ MGIT™ 960 
Mycobacterial Detection System (BD, United States) for 24 
days. Mycobacterium cell suspension (500 μL) was inoculated 
into 7.9 mL liquid medium 7H9 Middlebrook supplemented 
with OADC. The final concentration of M. tuberculosis in the 
sample was 105–106 CFU/mL. Each of the experiments with 
different tested substance concentrations, including control 
samples without any drug, was triplicated.
The antimycobacterial effect of the tested substances was 
estimated from the growth kinetics of M. tuberculosis H37Rv in 
the presence of a varied concentration of the tested substances 
compared with that in the absence of any drug [17]. Growth 
was monitored automatically every hour and recorded using 
Epicenter software (BD, United States). The mycobacterial 
growth was expressed in reference fluorescence units (RFU).
RESULTS AND DISCUSSION
We studied the inhibitory effect of synthesized 2´-deoxy-
nucleoside derivatives (Fig. 1, 6–10) carrying a long linear 
alkyl moiety introduced at position 5 of pyrimidine base via a 
oxymethyl group providing a higher flexibility of the hydro-
carbon chain than 1-alkynyl derivatives (1 and 2) described 
in the literature [11–14] on the growth of M. tuberculosis. The 
method of pyrimidine nucleoside methoxyalkyl derivative 
synthesis we have developed [15] is essentially easier and 
cheaper than the proposed method of 5-(1-alkynyl)-nucleo-
side synthesis [11–14]. To reveal the role of 3´-modification of 
the carbohydrate moiety in the anti-TB activity of 5-modified 
nucleosides, we have synthesized the following 2´-deoxyuri-
dine derivatives with the same substituent at position 5 of 
the base: 2´-deoxy-, 3´-azido-2´,3´-dideoxy-, and 3´-amino-
2´,3´-dideoxy-5-dodecyloxymethyluridine (Fig. 1, 8–10).
The data on the bacteriostatic activity of the studied sub-
stances from the growth of mycobacteria in the automated 
Bactec MGIT960 system demonstrated that the M. tuberculo-
sis H37Rv culture began to grow after 3.59 days in a medium 
without any drugs. The growth curve had a classic sigmoid 
shape with three phases: latent growth (before 3.59 days), 
exponential (log-phase or phase of active mycobacterial cell 
division) from 3.59 to 10.25 days, and a stationary one from 
10.25 days until the end of the experiment (Fig. 2). The dura-
tion of the active cell replication phase was 6.66 days.
To confirm the antimycobacterial activity of nucleosides 
and adjust the experimental conditions, we primarily tested 
5-(1-dodecynyl) and 5-(1-tetradecynyl)-2´-deoxyuridine (1 
and 2) at concentrations of 2, 20, and 200 μg/mL. According to 
published data [11], compounds 1 and 2 inhibited the growth 
of both M. bovis (MIC90 = 50 and 10 μg/mL, respectively) and 
M. avium by 50–70% at high concentrations. We showed that 
both substances taken at a concentration of 200 μg/mL com-
pletely inhibited the growth of M. tuberculosis culture.
5-Alkyloxymethyl derivatives of pyrimidine nucleosides 
(6, 7, 9, and 10) and nucleoside monophosphates (3–5) were 
tested at concentrations of 0.2, 2, 20, 100, and 200 μg/mL, and 
5-dodecyloxymethyl-2´-deoxyuridine (8) was tested at con-
centrations of 0.2, 2, 20, 50, and 100 μg/mL. The data of an 
experiment on determining the antimycobacterial activity is 
shown in Fig. 2.
A determination of the inhibitory effect of the substances 
6–10 on the culture of M. tuberculosis H37Rv has shown that 
Fig. 1. Structures of tested substances
№ X R1 R2 R3
1O H C 10H21 OH OH
2O H C 12H25 OH OH
3O H C 10H21 H2PO4 OH
4N H 2 C10H21 H2PO4 OH
5O H C 9H19 H2PO4 OH
6N H 2 C12H25 OH OH
7N H 2 C14H29 OH OH
8O H C 12H25 OH OH
9O H C 12H25 OH N3
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substance 6 led to 100% growth inhibition at concentrations 
of 200 and 100 μg/mL, 7 at concentrations of 200 and 100 μg/
mL, 8 at concentrations of 100 and 50 μg/mL, 9 at concentra-
tions of 200 and 100 μg/mL, and 10 at concentrations of 200 
and 100 μg/mL (Fig. 2). Thus, the minimal inhibitory concen-
tration (MIC) is 100 μg/mL for the substances 6, 7, 9, and 10 
and 50 μg/mL for the substance 8.
Nucleosides with large hydrophobic groups at position 5 
of the nucleic base are hardly soluble in water. To increase 
the solubility, we synthesized nucleoside 5´-monophosphates 
(3–5) by the method in [16]; however, these substances do not 
inhibit the growth of mycobacteria even at high (200 μg/mL) 
concentrations, and the growth kinetics in the presence of 
these substances is the same as in the control (in the absence 
of any drug).
We evaluated the active growth duration in the culture 
exposed to tested substances taken at concentrations not in-
ducing 100% inhibition of the culture growth in comparison 
with the control (Fig. 3). The data is given in relative units 
(RU) calculated as the ratio of the active replication time of 
the culture growing in the presence of a substance to that of 
the control culture (M. tuberculosis H37Rv without any sub-
stance added). Figure 3 shows that a more prolonged active 
replication phase is observed under exposition with 5-dodec-
yloxymethyl -2-deoxyuridine (8) and 5-dodecyloxymethyl-
3-amino-2,3-dideoxyuridine (10) taken at a concentration 
of 20 μg/mL, which is significantly different from the control 
(p < 0.01) and suggests a decrease in the intensity of myco-
bacterial-cell replication in the culture. Note that 24 and 18 h 
delays (for the substances 8 and 10, respectively) of mycobac-
terial growth when compared with the control were observed 
for these substances.
CONCLUSIONS
The inhibitory effect that 2-deoxyuridine and 2-deoxycyti-
dine derivatives with lengthy alkyloxymethyl moieties have 
on the growth of the M. tuberculosis H37Rv culture was first 
demonstrated in this work. 5-Dodecyloxymethyl -2-deoxy-
uridine (8) can be regarded as the most active against M. tu-
berculosis because of the lowest MIC of all tested compounds 
(50 μg/mL) and the most prominent capability of prolonging 
active cell replication and delaying the growth initiation at 
concentrations that do not cause 100% inhibition. Nonethe-
less, we have not revealed any fundamental difference in the 
inhibitory effect of pyrimidines differing both in the struc-
ture of the substituent (1-alkynyl or alkyloxymethyl moi-
ety) at position 5 of the base and the carbohydrate fragment 
(2-deoxy-, 3-azido-2,3-dideoxy-, or 3-amino- 2,3-dideoxyri-
bofuranose).
Thus, we have shown the capability of pyrimidine 2´-de-
oxynucleoside 5-methyloxyalkyl derivatives to inhibit the 
growth of M. tuberculosis in vitro; the most effective deriva-
tives could serve as prototypes for the development of new 
anti-TB drugs.  
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Fig. 2. Experiment on testing the antimycobacterial activity of sub-
stances. The growth kinetic plot is drawn for the M. tuberculosis H37Rv 
culture exposed to a varied concentrations of substance 9. RFU is the 
reference fluorescence unit monitored using the Epicenter software (BD, 
United States)
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Fig. 3. The efficacy of the substances inhibiting the M. tuberculosis 
culture growth at different concentrations. RE is the ratios between the 
active replication phase durations of the M. tuberculosis H37Rv culture 
exposed to the tested substances and that of the control culture, which 
was taken to be unity